top of page
Screenshot 2025-03-05 at 1.18.33 PM.png
Screenshot 2025-03-05 at 1.18.33 PM.png

The Purified Proteins as Drug Targets

The proteins/enzymes were purified to homogeneity, using baculovirus expression system (BEVS), having more than 99% purity and used as drug targets. Small molecules, identified using in-silico screening were tested for their inhibitory properties and finally tested against virus replication in the culture studies. In other aspects, a different combination of structural proteins of the SARS virus (membrane, membrane-envelope) were expressed in BEVS and tested for their immunogenicity in mice.

Screenshot 2025-03-05 at 1.18.33 PM.png

Hooda, P., et al. (2022). Molecules.

1-1 a HEVmtase.png
1-1 b corr-HEV Mtase.png

Inhibition of HEV Replication with MTase inhibitor

HEV Mtase

Hooda, P., et al. (2023). ACS Omega.

Inhibition of HEV RNA replication with RdRp inhibitors

HEV RdRp

Kumar, A., et al. (2023). Journal of Enzyme Inhibition and Medicinal Chemistry.

      Inhibition of HEV replication with Helicase inhibitor

HEV Helicase 

Saraswat, S., et al. (2020). Frontiers in Cellular and Infection Microbiology.

1-4 a HEV Cysteine Protease.png
1-4 b corr- HEV Cysteine Protease.png

Inhibition of HEV Cysteine protease 

with protease inhibitors

HEV Cysteine protease 

Trivedi, A., et al. (2023). The FEBS Journal.

2-1 a SARS Cov2-Mpro.png
2-1 b corrSars Cov2-Mpro.png

Inhibition of SARS-CoV-2  replication 

with MPro inhibitors

SARS CoV-2 MPro 

Trivedi, A., et al. (2025). The FEBS Journal.

2-2 a SARS Cov2- PL Pro.png
2-2 b corr-Sars Cov2-PL Pro.png

Inhibition of SARS-CoV-2  replication 

with PL Pro inhibitors

SARS CoV-2 PLPro 

                                 Submitted

          IgG levels with M VLPs

SARS CoV-2 Membrane VLPs

                               Submitted

          IgG levels  with M-E VLPs

SARS CoV-2 Membrane-Envelope  VLPs 

bottom of page